MA28639B1 - Vaccins - Google Patents

Vaccins

Info

Publication number
MA28639B1
MA28639B1 MA29494A MA29494A MA28639B1 MA 28639 B1 MA28639 B1 MA 28639B1 MA 29494 A MA29494 A MA 29494A MA 29494 A MA29494 A MA 29494A MA 28639 B1 MA28639 B1 MA 28639B1
Authority
MA
Morocco
Prior art keywords
vaccines
Prior art date
Application number
MA29494A
Other languages
English (en)
Inventor
Claudine Elvire Marie Bruck
Vincent Brichard
Remi M Palmantier
Melinda Meaders
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA28639B1 publication Critical patent/MA28639B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA29494A 2004-05-04 2006-11-28 Vaccins MA28639B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0409940.4A GB0409940D0 (en) 2004-05-04 2004-05-04 Vaccine

Publications (1)

Publication Number Publication Date
MA28639B1 true MA28639B1 (fr) 2007-06-01

Family

ID=32482653

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29494A MA28639B1 (fr) 2004-05-04 2006-11-28 Vaccins

Country Status (16)

Country Link
US (1) US20070243196A1 (fr)
EP (1) EP1755657A2 (fr)
JP (1) JP2007536326A (fr)
CN (1) CN1980691A (fr)
AU (1) AU2005237256A1 (fr)
BR (1) BRPI0510570A (fr)
CA (1) CA2564470A1 (fr)
GB (1) GB0409940D0 (fr)
IL (1) IL178681A0 (fr)
MA (1) MA28639B1 (fr)
MX (1) MXPA06012723A (fr)
NO (1) NO20065480L (fr)
NZ (1) NZ550967A (fr)
RU (1) RU2006138283A (fr)
WO (1) WO2005105139A2 (fr)
ZA (1) ZA200608693B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186049A1 (en) * 2006-05-26 2009-07-23 Vincent Brichard Method of treating mage positive cancer
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
DK2118128T3 (da) * 2007-01-15 2013-02-18 Glaxosmithkline Biolog Sa Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1
HUE035762T2 (en) 2007-03-13 2018-05-28 Univ Zuerich Monoclonal Human Tumor-Specific Antibody
KR20110091817A (ko) * 2007-05-24 2011-08-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
WO2009127666A2 (fr) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Procédé et compositions
CN101381402B (zh) * 2008-10-20 2011-06-01 中国人民解放军第三军医大学 Ny-eso-1肿瘤抗原模拟表位及其应用
EA021100B1 (ru) 2009-03-17 2015-04-30 МДхХЭЛС СА Усовершенствованное определение экспрессии генов
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
KR101614997B1 (ko) * 2011-01-10 2016-04-22 씨티 아틀란틱 엘티디. 종양 관련 항원 결합 항체를 포함하는 조합 요법
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
RU2627447C2 (ru) * 2013-05-14 2017-08-08 ЗОИТИС СЕРВИСЕЗ ЭлЭлСи Новые вакцинные композиции, содержащие иммуностимулирующие олигонуклеотиды
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
EP3508198A1 (fr) 2014-06-04 2019-07-10 Exicure, Inc. Libération polyvalente de modulateurs immunitaires par des acides nucléiques sphériques liposomaux pour des applications prophylactiques ou thérapeutiques
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
WO2016019298A2 (fr) * 2014-08-01 2016-02-04 Texas Tech University System Protéine de sperme 17 antigène testiculaire du cancer utilisée en tant que cible pour l'immunothérapie et le diagnostic du cancer du sein
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
US11945851B2 (en) 2017-06-07 2024-04-02 The Wistar Institute Of Anatomy And Biology MAGE-A vaccines and methods of treatment using the same
WO2019061297A1 (fr) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 Peptide de fusion d'épitope de lymphocyte t auxiliaire cd4 et vaccin associé
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US6055099A (en) * 1996-02-23 2000-04-25 British Telecommunications Public Limited Company Optical interconnect
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens

Also Published As

Publication number Publication date
ZA200608693B (en) 2010-01-27
WO2005105139A2 (fr) 2005-11-10
NO20065480L (no) 2006-11-28
CN1980691A (zh) 2007-06-13
WO2005105139A3 (fr) 2006-04-13
BRPI0510570A (pt) 2007-11-20
AU2005237256A1 (en) 2005-11-10
NZ550967A (en) 2009-01-31
GB0409940D0 (en) 2004-06-09
EP1755657A2 (fr) 2007-02-28
CA2564470A1 (fr) 2005-11-10
US20070243196A1 (en) 2007-10-18
RU2006138283A (ru) 2008-06-10
MXPA06012723A (es) 2007-02-14
IL178681A0 (en) 2007-02-11
JP2007536326A (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
MA28609B1 (fr) Vaccins
MA28639B1 (fr) Vaccins
MA28885B1 (fr) vaccins
DK1959991T3 (da) Terapeutisk vaccine
TWI365191B (en) Vaccine
DK1968631T3 (da) Vaccine
GB2434367B (en) Improved vaccines
ATE462445T1 (de) Prrs-impfstoffe
GB0504436D0 (en) Vaccine
ATE450271T1 (de) Impfstoff
BRPI0607474A2 (pt) vacinação enriquecida com glicosido-alquila
IS8325A (is) Bóluefni
GB0411150D0 (en) Vaccine
GB0413510D0 (en) Vaccine
GB0412407D0 (en) Vaccine
GB0428381D0 (en) Vaccine
AP2709A (en) An anti-theileriosis vaccine
GB0406598D0 (en) Vaccine
GB0419918D0 (en) Vaccine
GB0425339D0 (en) Vaccine
GB0416398D0 (en) Vaccine
GB0416833D0 (en) Vaccine
GB0413154D0 (en) Vaccine
GB0413371D0 (en) Vaccine
GB0412547D0 (en) Vaccine